Abstract: To evaluate the antitumor efficacy and impact of concomitant treatment with Gefitinib combined with Gamma Stereotactic Radiosurgery ( SRS ) and whole-brain radiotherapy ( WBRT ) in patients with brain metastases from NSCLC. Methods: Twenty-three NSCLC patients with brain metastases were reviewed retrospectively. All of them were treated with concomitant treatment of gefitinib, SRS and WBRT. The efficacy, toxicity, and survival were investigated. Results: In terms of intracranial lesions, the objective response rate ( ORR ) and the disease control rate ( DCR ) were 78.3% ( 18/23 ) and 91.3% ( 21/23 ), respectively. As for systemic disease, ORR and DCR were 21.7% ( 5/23 ) and 73.9% ( 17/23 ), respectively. The median time to disease progression （TDP） was 8.3 months, whereas the median overall survival ( OS ) time was 12.8 months. Univariate analysis showed that the KPS score, tumor volume, histological type, and RPA class were predictive factors for TDP ( P = 0.000, 0.038, 0.048, and 0.000 ). The KPS score, tumor volume, and RPA class were predictive factors for OS of the patients ( P = 0.000, 0.002, 0.004 ). The most common toxicities were rash and diarrhea, but all were well-tolerated. Conclusion: The current experimental data suggested that gefitinib concomitant with SRS and WBRT was very effective and safe for patients with brain metastases from NSCLC. The patients with better KPS score, RPA class, smaller tumor volume, and adenocarcinoma may have better survival rates.